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ABSTRACT
Congenital factor V (FV) deficiency is a bleeding disorder associated with mild
to severe hemorrhagic symptoms and a prevalence in the general population of 1 in
1,000,000 in the homozygous form. Patients with FV deficiency and clinically significant
manifestations (mainly involving mucosal tracts) show very low or unmeasurable plasma
FV levels and are usually homozygous or compound heterozygous for mutations located
in the FV gene (F5). Heterozygous carriers have approximately half-normal levels of FV
and are usually asymptomatic. Replacement therapy for FV-deficient patients can only
rely on administration of fresh-frozen plasma because specific FV concentrates are
unavailable and FV is not present in cryoprecipitate or prothrombin complex concen-
trates. A total of 56 mutations have been published to date as being responsible for severe
or moderately severe FV deficiency; more than two thirds of these are null mutations
(mainly decreasing FV expression), with the remaining being missense mutations
(usually impairing FV secretion). This article will provide a concise description of the
FV protein and gene and will review the molecular, clinical, and therapeutic aspects of
FV deficiency.
KEYWORDS: Factor V, factor V deficiency, mutational spectrum, clinical
manifestations, treatment
Coagulation factor V (FV), also known as pro-
accelerin or labile factor, is the protein cofactor required
by the prothrombinase complex for thrombin gener-
ation.1 FV also represents an important modulator in
the early phase of blood clot formation, as it contributes
to the anticoagulant pathway by downregulating
factor VIII (FVIII) activity.1 FV was discovered in
1947 by the Norwegian hematologist Paul Owren while
studying a woman affected by a hemophilia-like syn-
drome.2 Given the double role of FV in the coagulation
process, deficiencies in FV activity and/or antigen levels
may result in either hemorrhagic or thrombotic
tendencies. Here, an overview concerning the bleeding
disorder (from laboratory diagnosis to the molecular
characterization of FV-deficiency–causing mutations)
is reported.
FV DEFICIENCY
FV deficiency is a rare bleeding disorder with a preva-
lence of 1 per million in the general population.3 It
is inherited as an autosomal recessive trait (Online
Mendelian Inheritance in Man, OMIMþ227400);
parental consanguinity is often present, especially in
countries (e.g., Muslim countries and southern India)
where consanguineous marriages are frequent and where
the disorder occurs up to 10 times more frequently than
it does in the Western world.4
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FV deficiency can be classified as (1) type I
deficiency, or cross-reacting material negative (CRM–)
defect, with concordantly low or unmeasurable antigen
and functional levels (quantitative defect); (2) type II
deficiency, or CRMþ defect, with normal or mildly
reduced antigen level associated with reduced coagulant
activity (qualitative defect).
Severe FV deficiency (formerly known as para-
hemophilia) is characterized by FV levels below 10 to
15% and represents the phenotypic expression of muta-
tions in the homozygous or compound heterozygous
state, whereas mild to moderate FV deficiency, showing
FV plasma levels >20 to 30%, is usually associated with
mutations in the heterozygous state.
CLINICAL MANIFESTATIONS
More than 200 cases of FV deficiency have been
described in the literature, the largest clinical studies to
date concerning 35 patients from Iran4 and 37 patients
collected in the North American Rare Bleeding Disorder
Registry.5
The Iranian study was exclusively focused on
patients suffering from severe FV deficiency: among
them, the first bleeding episodes occurred during the
first 6 years of life, although only one patient bled from
the umbilical cord. Mucosal tract bleedings can be
considered the main clinical features of these patients;
epistaxis, menorrhagia, and oral cavity hemorrhages
being observed quite frequently (60% frequency for
each of these symptoms). Hematomas and hemarthroses
occurred in only one quarter of patients, and life-threat-
ening bleeding episodes in the central nervous system
and in the gastrointestinal tract were extremely rare.4 A
clear confirmation of this clinical spectrum comes from
the American registry,5 which also described 19 subjects
with moderate FV deficiency. Typically, these patients
are difficult to diagnose and often come to medical
attention because of a positive family history or of an
abnormal preoperative laboratory screen.3,5 Those who
are symptomatic present with skin and mucous mem-
brane bleeding (62%), whereas musculoskeletal and
genitourinary episodes account for the remainder (19%
each).5
LABORATORY ASSAYS
Phenotype Analysis
FV deficiency can be initially diagnosed observing a
prolongation of both the prothrombin time (PT) and
activated partial thromboplastin time (APTT) in asso-
ciation with a normal thrombin time (TT). Both PT and
APTT are corrected by mixing the patient plasma with a
‘‘normal’’ plasma pool. Deficiency of FV should be
confirmed by a PT-based FV assay. It should be kept
in mind that individuals having reduced FV should also
be tested for FVIII to exclude the occurrence of com-
bined FV and FVIII deficiency.6
Genotype Analysis
THE FV GENE
The gene coding for human FV (F5) comprises 25
exons, covers a genomic region of 74.5 kb, and maps
to the 1q24.2 chromosomal region (UCSC Genome
Browser: http://genome.ucsc.edu/).7F5 is mainly ex-
pressed by hepatocytes, and there are indications that
FV can be synthesized in vivo in the megakaryocyte/
platelet lineage.8–11
Very recently, analysis of the F5 splicing pattern
in HepG2 cells and human liver evidenced the occur-
rence of multiple alternative splicing (AS) events.12 In
particular, among different unproductive ASs, three
major ones were detected: two determining the synthesis
of in-frame splicing variants and one producing an out-
of-frame transcript. The latter was demonstrated to be
downregulated by the nonsense-mediated mRNA decay
(NMD) pathway, a mechanism that selectively detects
and degrades transcripts carrying premature termination
codons.13 This suggests a possible role of the AS-NMD
coupling mechanism in the regulation the F5 gene
expression.12,14
THE FV PROTEIN
The 6.9-kb FV cDNA15 codes for a 330-kDa mature
protein of 2196 amino acids,16 preceded by a 28-residue
leader peptide. FV is characterized by a domain struc-
ture (A1-A2-B-A3-C1-C2) similar to that of the
highly homologous FVIII,1 with which it shares
40% sequence identity. The only FV region with no
significant sequence similarity to any known protein is
the B domain,17 which contains two tandem repeats of
17 amino acids and 31 tandem repeats of 9 amino acids.
FV has 19 cysteines, 14 of which are involved in
disulfide bridges,18,19 and is characterized by multiple
posttranslational modifications (multiple N-linked
glycosylation sites are especially present in the B
domain).20
To date, only the three-dimensional structure of
the C2 domain of human FV has been determined by
x-ray crystallography; the C2 domain shows an eight-
stranded b-barrel core from which three spikes protrude.
These spikes mediate binding of activated FV (FVa)
to phospholipid membranes.21 The description of the
crystal structure of activated protein C–inactivated
bovine FVa allowed the reconstruction of a complete
molecular model for FVa,22 showing that the two
C domains are aligned ‘‘edge-to-edge’’ to form a plat-
form that lifts the A domains (arranged around a
pseudo-threefold axis to form a six-bladed wheel) to an
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appropriate height above the membrane for interaction
with their physiologic partners. Very recently, this model
was substantially confirmed by (a) the low-resolution
human FVa three-dimensional structure obtained by
Stoilova-McPhie and colleagues,23 which also suggested
that the two juxtaposed C domains are inserted deeper
into the lipid bilayer than has been previously thought;
(b) the solvent-equilibrated model of human FVa pro-
posed by Lee and Chandrasekaran,24 which also indi-
cated a possible significant shift toward planarity in the
arrangement of the five FVa domains.
FV has little or no intrinsic procoagulant activity
until it is converted to FVa by thrombin or activated
factor X (FXa) by cleavages at three arginine residues
(Arg709, Arg1018, Arg1545). The released FVa, lacking
the entire B domain, is composed of a 105-kDa heavy
chain (A1-A2 domains) and a 74- or 71-kDa light chain
(A3-C1-C2 domains), held together by a single calcium
ion.1,17 Upon activation, FVa assembles with FXa on
phospholipid membranes, forming a complex that en-
hances the rate of prothrombin activation by nearly
300,000-fold. Downregulation of the procoagulant
activity of FVa is achieved by activated protein C–
mediated proteolysis at Arg506, Arg306, and Arg679
residues.1
MUTATIONAL SPECTRUM
Among rare inherited coagulopathies, FV deficiency is
one of the least characterized from the molecular point
of view, with only 56 genetic defects hitherto de-
scribed.12,25–38 All mutations are located in F5, and
those fully published to date are listed in Fig. 1. A very
up-to-date database on FV mutations has been compiled
by Dr. Hans L. Vos, including also mutations reported
in abstract form.39 The last release (September 15, 2008)
is available on request (e-mail: H.L.Vos@lumc.nl).
Concerning severe type I FV deficiency, a total of
48 mutations have been described, only one being
recurrent (Tyr1702Cys, repeatedly found in Italian in-
dividuals).40 This confirms the remarkable allelic heter-
ogeneity of the disease. The 48 identified mutations
correspond to 21 small insertion/deletion (44%), 14
missense mutations (29%), 7 splicing defects (15%),
and 6 nonsense mutations (12%).
As for mild type I FV deficiency, besides the
recurrent Tyr1702Cys mutation, seven additional ge-
netic defects have been reported to date in heterozygous
index patients (this survey does not take into account
heterozygous relatives of severe FV-deficient patients).
Again, all types of point mutations are represented: three
nonsense, two missense, one splicing, and one insertion/
deletion mutation.
A decrease in FV levels, responsible for a mild
type I deficiency, has also been associated with two FV
variants (Fig. 1): a functional polymorphism
(Met2120Thr), which was demonstrated to cause an
25% reduction in FV levels,41 and the HR2 haplotype
(named after the His1299Arg polymorphism). HR2 is a
FV allele defined by a group of more than 10 poly-
morphisms42; among them, the dominant contribution
of the Asp2194Gly variant was demonstrated by expres-
sion experiments in eukaryotic cells.43
Although the first to be described, FV-New
Brunswick (Ala221Val) is the only genetic defect asso-
ciated with type II deficiency.44 The expression of the
recombinant FV-Ala221Val demonstrated that the mu-
tation interferes with the stability of mutant FVa.45
In summary, mutations causing FV deficiency do
not cover the full spectrum of possible genetic lesions, as
mutations located in the promoter (or other regulatory
regions) as well as large deletions are absent. Moreover,
an uneven distribution of mutations is observable: most
genetic defects are present in exons from 8 to 25, but
missense mutations are completely absent in the large
exon 13, coding for the whole B domain. This can
probably be explained by an increased ‘‘tolerance’’ of
this domain to variations, as suggested by the fact that
it is highly polymorphic and not evolutionarily con-
served.
PATHOGENIC MECHANISMS
Given that mutant FV molecules are present in the
bloodstream of the patients at very low levels, the
demonstration of the pathogenic role of missense muta-
tions in F5 has relied on expression studies in mamma-
lian cell lines.
This approach was extremely useful in defining a
common denominator for missense mutations: ex-
pressed FV mutant proteins have been in most cases
associated with both a secretion impairment and intra-
cellular degradation, probably because of their impaired
folding and/or conformational changes leading to re-
tention by the quality control system of the secretory
pathway.25,33,35,36
With respect to splicing defects, FV platelet and
peripheral blood mononuclear cell expression was ex-
ploited to provide easy access to mature F5 mRNA.
When suitable specimens from FV-deficient patients
were unavailable to perform studies at the RNA level,
expression of appropriate minigene constructs in eukary-
otic cells proved to be an effective tool to unravel the
consequences of splicing mutations. In the majority of
cases, splicing defects were demonstrated to cause the
disruption of a preexisting splice site resulting in exon
skipping, whereas the opposite situation (i.e., the acti-
vation of a cryptic splice site) appeared a less frequent
event.12,25
Finally, mutations introducing premature termi-
nation codons have been investigated in some cases at
the mRNA level, invariantly showing selective degra-
dation of the corresponding transcript by the NMD
pathway.25,31
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Figure 1 Mutational spectrum of severe and mild FV deficiency. All known causative mutations for type I (CRM–) and type II
(CRMþ) FV deficiency are presented according to their position within F5. Exons and introns are represented by boxes and
lines, respectively, and are not drawn to scale. The FV domain structure is also indicated. Mutations are named on the basis of
their predicted effect at the protein level (numbering omitting the signal peptide), except for splicing mutations, which are
reported according to their nucleotide position (numbering according to the cDNA sequence of F5, GenBank accession no.
M16967). As for frameshift mutations, the corresponding nucleotide variation is shown in parentheses. Only full-published
mutations are listed. Mutations causing severe FV deficiency found in at least one patient in the homozygous state are set in
boldface. The only mutation found both in severe and in mild FV-deficient patients (Tyr1702Cys) is underlined. Mutations
belonging to the HR2 haplotype are highlighted in gray.
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MOLECULAR DIAGNOSIS
Knowledge of the existence of founder effects for
specific mutations can be useful to lower the costs and
speed up the procedures for the molecular diagnosis of
the disease and for its prevention by prenatal diagnosis.
This is especially true for those countries where the
disorder is highly prevalent (high level of inbreeding)
and the resources (facilities and budget) are not abun-
dant. With respect to FV deficiency, genotyping is
complicated by the overall paucity of recurrent muta-
tions (except for Tyr1702Cys among Italians), which
makes it necessary to sequence the whole coding region
of the gene as well as its boundaries in each family. To
speed up the procedures for the molecular diagnosis, a
straightforward approach could be to first screen exons
showing the higher density of reported mutations. In
particular, the large exon 13, which is apparently
enriched in mutations but also shows a ‘‘mutation
density’’ quite lower than the rest of the gene, and
whose sequencing is made difficult by the presence of
repeated regions, should be initially left aside. More-
over, to save resources and time, the adoption of a
DNA-pooling strategy applied to direct sequencing
should be taken into account.46
The use of a prescreening technique, such as
single-strand conformation polymorphism (SSCP),
high-performance liquid chromatography (DHPLC),
or high-resolution melting (HRM), can also be consid-
ered, even though these approaches are hindered by the
particular structure of the F5 gene, whose coding region
is half contained in a unique exon (exon 13, 2820-bp
long), is enriched in repeats, and shows a high number of
single nucleotide polymorphisms.
Genotype/Phenotype Correlations
From mining of the literature, no clear genotype/phe-
notype correlations clearly emerge between the clinical
expression of FV deficiency, plasma FV levels, and the
corresponding associated mutations. In fact, patients
often present a more severe bleeding phenotype than
do others, although they carry the same mutation or
show similar FV levels. A possible explanation for these
discrepancies could be the different genetic background
of patients: for instance, the co-inheritance of FV-
deficiency alleles with risk factors for thrombophilia
and/or with alleles of modifier genes can influence the
overall coagulation cascade, hence affecting the pheno-
typic expression of the disease. Interestingly, the possi-
bility that severe FV-deficient phenotype may be
modulated by a concomitant procoagulant defect was
recently investigated by Duckers and colleagues.47 They
showed that congenital FV deficiency is associated with
reduced plasma levels of tissue factor pathway inhibitor
(TFPI), which decreases the FV requirement for mini-
mal thrombin generation in FV-deficient plasma to less
than 1%, thus probably protecting FV-deficient patients
from severe life-threatening bleeding.47
PROBLEMS WITH LABORATORY
EVALUATION
Phenotype Analysis
Because the phenotype evaluation of FV deficiency is
initially based on PT and APTT assays, which are both
variably prolonged in these patients, it is recommended
to follow the published guidelines stating how to
handle and process plasma samples.48 More recently,
Zu¨rcher et al.49 investigated the stability of coagulation
assays in citrated whole blood transported at ambient
temperature, as the stated time limit of 4 hours for non-
heparin APTT poses significant constraints to testing
in centralized coagulation laboratories. They concluded
that clinically significant changes were observed for FV
coagulant activity (FV:C) and FVIII coagulant activity
(FVIII:C) starting only at 24 to 28 hours, distinct from
all other coagulant factors that were found to be more
stable.
Genotype Analysis
In our personal experience on 45 screened patients with
severe or mild FV deficiency, in up to 20% of cases the
molecular diagnosis was lacking or incomplete, even after
an extensive mutational screening of the gene. Multiple
possible explanations can be proposed: (a) PCR-based
mutational screenings can miss large heterozygous dele-
tions or large-scale chromosomal rearrangements; (b)
deep-intronic mutations are overlooked by conventional
coding-region–focused methods; (c) underestimation of
the pathogenic role of sequence variants (e.g., synony-
mous substitutions in the coding sequence interfering
with splicing).
Hopefully, the decrease of sequencing costs and
the possibility to automate the entire screening workflow
will allow a faster and more thorough genetic diagnosis
in the near future.
PRENATAL DIAGNOSIS
In developing countries, where management is still
largely inadequate, patients with rare bleeding disor-
ders (RBDs) rarely live beyond childhood. Thus, mo-
lecular characterization, carrier detection, and prenatal
diagnosis remain the key steps for preventing the birth
of children affected by coagulation disorders or for the
preparation of on-demand treatment in case of neonatal
hemorrhages. For FV deficiency, although life-threat-
ening episodes at birth are rare, the use of prenatal
diagnosis can be advisable only in those families
with severe clinical history, previously presenting
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affected members. The choice of the strategy (direct or
indirect), as well as the choice of the sample to test (e.g.,
amniocytes or chorionic villi) depends on the effective
available budget and facilities to achieve the largest
benefit.
THE BEST SCHEME OF TREATMENT
The choice of dosages and modalities of treatment of
bleeding episodes is based on the type of bleeding, on
FV levels, and on FV plasma half-life (36 hours).
Replacement therapy with FV can be administered
only through fresh-frozen plasma (FFP), preferably
virus-inactivated, because FV concentrates are unavail-
able and FV is not present in cryoprecipitate or pro-
thrombin complex concentrates.50 FV levels should be
raised to at least 15 IU/dL51 by using 15 to 20 mL/kg
FFP.52 The initial dose should be 15 to 20 mL/kg
followed by smaller amounts, such as 5 mL/kg every 12
hours, adjusting the dosage on the basis of FV levels,
PT, and APTT. Studies of FV recovery recommend
maintaining a level of 20 to 25% of FV activity for
surgery or in case of severe bleeding.51 Surgical proce-
dures should be addressed by administering FFP once a
day to achieve minimum levels of FV of 25 IU/dL until
wound healing is established.51
It has been suggested that in cases of severe
bleeding not controlled with FFP replacement or in
case of inhibitor development, platelet transfusions
may be considered. A case of severe FV deficiency
associated with multiple episodes of intracranial bleeding
at birth was reported, where the inhibitor development
due to FFP infusion was solved by additional admin-
istration of platelets.53 Platelets provide a concentrated
supply of FV (20% of total circulating FV). Therefore,
after a-granule release upon platelet activation, FV can
presumably bind immediately to surface receptors opti-
mizing prothrombinase complex activity.51
Complications of Treatment
Development of alloantibodies to FV in FFP is a
potential complication of hereditary FV deficiency.51
After FFP replacement therapy, the occurrence of in-
hibitors, especially transient ones of low level, may be
common51 and can be neutralized using large amounts of
FFP.50 However, as in the treatment of surgical cases,
there are concerns over fluid overload in this situation,
and close cardiovascular monitoring is hence advisable.
Intravenous immunoglobulin may also be effective in
eradicating the FV inhibitor.54 Platelet infusions have
been reported to be effective in acquired FV deficiency,55
but it was reported to be effective in stabilizing a
subdural hematoma also in a patient with hereditary
FV deficiency complicated by inhibitors.56 Use of re-
combinant activated factor VII (rFVIIa) concentrate was
reported at a dosage varying between 80 to 100 mg/kg
administrated intravenously, however the hemostatic
efficacy in these patients was variable.57–59
Treatment in Women: Pregnancy, Delivery,
and Menorrhagia
Menorrhagia is a common bleeding symptom in women
with severe FV deficiency. Management of this symptom
includes medical treatment such as antifibrinolytics
(epsilon-aminocaproic acid at 50 to 60 mg/kg every
4 to 6 hours; tranexamic acid at 15 mg/kg, 1 g every
6 to 8 hours, orally or intravenously), oral contraceptives,
levonorgestrel intrauterine device and replacement
therapy, and surgical treatments such as endometrial
ablation and hysterectomy.60 However, management of
women with FV deficiency requires close monitoring of
FV levels to ensure that the minimum hemostatic level
of 15 IU/dL has been achieved and awareness of the
increased risk of bleeding with any surgical interven-
tions.60 There are no published data on management of
pregnancy in women with FV deficiency.51 FV levels in
pregnancy do not consistently increase or decrease, hence
FV levels should be maintained above the hemostatic
level of 15 IU/dL during labor, using preferably virus-
inactivated FFP as the source of the factor. If a cesarean
section is performed, it would be prudent to continue FV
replacement to maintain PT and APTT in the normal
range until wound healing is complete in women with
FV levels of <15 IU/dL.51
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